Uploaded December 2021 | Updated September 2026, 2 weeks ago
Purification of enveloped viruses and virus-like particles presents several challenges due to their large size and complexity. This webcast details the importance of resin screening, endonuclease treatment, process development, and the scale-up purification of a retrovirus-like particle intended for use in human subjects. The resulting current good manufacturing practice (CGMP) compatible process required approximately four hours to purify 240 L of nuclease-treated bioreactor harvest and resulted in a 99% reduction in process volume and up to 65% recovery of virus particles with a final purity consistent with requirements for clinical trials. This process using Nuvia Q Anion Exchange Resin, is readily scalable, fast, low cost, simple, and CGMP compatible and can be used for the capture step in clinical-grade manufacture of retrovirus vectors.
Overview:
-Retrovirus vectors and associated analytical methods
-Scale-down modeling
-Chromatographic parameters
-Process scale-up execution and evaluation
Learn more at bio-rad.com/en-us/process-separations/support/webinars?ID=KVY6W0MNI
Subscribe to the Bio-Rad channel: youtube.com/user/BioRadLifeScience?sub_confirmation=1
We Are Bio-Rad.
Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.
Connect with Bio-Rad Online:
Website: bio-rad.com
LinkedIn: linkedin.com/company/1613226
Facebook: facebook.com/biorad
Twitter: twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs
©2021 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Music used by permission granted by royalty-free license from Pond5.com
Purification of enveloped viruses and virus-like particles presents several challenges due to their large size and complexity. This webcast details the importance of resin screening, endonuclease treatment, process development, and the scale-up purification of a retrovirus-like particle intended for use in human subjects. The resulting current good manufacturing practice (CGMP) compatible process required approximately four hours to purify 240 L of nuclease-treated bioreactor harvest and resulted in a 99% reduction in process volume and up to 65% recovery of virus particles with a final purity consistent with requirements for clinical trials. This process using Nuvia Q Anion Exchange Resin, is readily scalable, fast, low cost, simple, and CGMP compatible and can be used for the capture step in clinical-grade manufacture of retrovirus vectors.
Overview:
-Retrovirus vectors and associated analytical methods
-Scale-down modeling
-Chromatographic parameters
-Process scale-up execution and evaluation
Learn more at bio-rad.com/en-us/process-separations/support/webinars?ID=KVY6W0MNI
Subscribe to the Bio-Rad channel: youtube.com/user/BioRadLifeScience?sub_confirmation=1
We Are Bio-Rad.
Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.
Connect with Bio-Rad Online:
Website: bio-rad.com
LinkedIn: linkedin.com/company/1613226
Facebook: facebook.com/biorad
Twitter: twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs
©2021 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Music used by permission granted by royalty-free license from Pond5.com
